New Drugs for Antibacterial Therapeutics Coming Down the Pipeline, 2018 : Researchmoz

Researchmoz added Most up-to-date research on "Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance" to its huge collection of research reports.

Antibacterial resistance is currently believed to be responsible for over 700,000 deaths each year. As antibiotic resistance increases, due to the overuse and misuse of antibiotics, the number of avoidable deaths is expected to increase, with one study predicting there will be 10 million deaths caused by bacteria resistant to antibiotics in 2050.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1555712

There are several techniques being utilized to combat the spread of antibiotic resistance, which range from combining antibiotics to increase efficacy to reducing the use antibiotics in both humans and livestock.
However, significantly reducing the number of deaths caused by antibacterial resistance will require the development of new antibacterials that target infections caused by the most deadly and antibiotic resistant bacteria while acting on targets not currently utilized by marketed products in order to avoid cross resistance.

Without the development of innovate antibacterial products the emergence and spread of antibiotic resistance will not only increase the number of avoidable deaths caused by the infection itself, it also has the potential to increase the risks associated with surgery, while putting additional pressure on already stretched healthcare providers, as treating drug-resistant infections is considerably more expensive than treating drug-susceptible infections.

This report examines the entire antibacterial therapy area with a particular focus on four key indications, methicillin resistant staphylococcus aureus (MRSA), sepsis, pneumonia and tuberculosis, which were selected due to their pipeline size, prevalence and level of unmet need.

Scope

The antibacterial pipeline is large, with 1,634 products in active development. Does current pipeline innovation hold the potential to affect the future antibacterial market?
The four key indications in the antibacterial pipeline are tuberculosis, pneumonia, MRSA and sepsis. How does the composition of each pipeline compare both in terms of first-in-class and non-first-in-class innovation.
There are 234 first-in-class products in the antibacterial pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?
Analysis of strategic consolidations and deals revealed a high level of activity between 2006 and 2017.
A significant number of first-in-class products have been identified with no prior involvement in deals. How does deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Get complete TOC with Tables and Figures at: https://www.researchmoz.us/antibacterial-therapeutics-high-levels-of-pipeline-innovation-focused-on-the-increasing-unmet-need-associated-with-antibiotic-resistance-report.html/toc

Reasons to buy

Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
Visualize the composition of the antibacterial therapeutics market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
Analyze the antibacterial pipeline and stratify by stage of development, molecule type and molecular target.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, human first-in-class targets have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

List of Table

Table 1: Antibacterial Therapeutics, Quick-Sequential Oran Failure Assessment Test Criteria 12
Table 2: Antibacterial Therapeutics, Glasgow Coma Scale 12
Table 3: Antibacterial Therapeutics, Sequential Organ Failure Assessment score 13
Table 4: Antibacterial Therapeutics, Monocyte Differentiation Antigen CD14 as a Therapeutic Target, 2017 41
Table 5: Pipeline Programs Targeting Monocyte Differentiation Antigen CD14 41
Table 6: Antibacterial Therapeutics, Toll-Like Receptor 3 as a Therapeutic Target, 2017 42
Table 7: Pipeline Programs Targeting Toll-Like Receptor 3 42
Table 8: Antibacterial Therapeutics, Gelsolin as a Therapeutic Target, 2017 43
Table 9: Pipeline Programs Targeting Gelsolin 43
Table 10: Antibacterial Therapeutics NACHT LRR and PYD Domains Containing Protein 3 as a Therapeutic Target, 2017 45
Table 11: Pipeline Programs Targeting NACHT LRR and PYD Domains Containing Protein 3 45

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1555712

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger at : https://marketreportandanalysis.blogspot.com

This release was published on openPR.